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Deﬁnition of Terms
 
Algorithm 
 
— The sequence in which assays are performed to detect HIV antibody in a body fluid.
 
Confidence Interval — 
 
An interval estimate of a population parameter computed so that the 
statement “the population parameter lies in this interval” will be true at a stated confidence, 
usually 95%.
 
Evaluation
 
 — A process for determining whether a test system meets defined needs in the 
potential user’s environment.
 
Evaluation Panel — 
 
Specimens that are used during the evaluation for which the serostatus has 
been previously defined by the gold standard.
 
External Quality Assessment (EQA)
 
 — A program that allows laboratories or testing sites to 
assess the quality of their performance by comparison of their results with other laboratories, 
through analyzing proficiency panels, or blind rechecking.  EQA also includes on—site 
evaluation of the laboratory to review the quality of test performance and operations.
 
Gold Standard
 
 — A country defined algorithm for determining a sample’s true serostatus.  
 
National Reference Laboratory
 
 — A nationally recognized laboratory with appropriate testing 
capabilities and facilities for performing or providing access to confirmatory HIV testing 
sufficient to determine HIV status. 
 
Negative predictive value — 
 
In HIV testing, the probability that when a test is non-reactive, the 
specimen does not have antibody to HIV.
 
Positive predictive value —
 
 In HIV testing, the probability that when a test is reactive, the 
specimen actually contains antibody to HIV.
 
Prevalence — 
 
The percentage of persons in a given population with a disease or condition at a 
given point in time.
 
Proficiency testing panel — 
 
A set of approximately 3-5 samples with known values used to 
assess the performance capabilities of testing personnel.
 
 
Quality Assurance 
 
— Planned and systematic activities to provide adequate confidence that 
requirements for quality will be met. 
 
Quality Control — 
 
Operational techniques and activities that are used to fulfill requirements for 
quality.
 
Reference Panel — 
 
Aliquotted, stable serum or plasma specimens that have been highly 
characterized; known
 
 
 
cutoff points, subtype, titer, etc.
 
Sensitivity of a test — 
 
A measure of the probability for correctly identifying an HIV-infected 
person.
 
Serum Library
 
 — A source of serum specimens from which a panel is drawn for evaluation 
purposes.
 
Specificity of a test 
 
— A measure of the probability of correctly identifying an HIV-uninfected 
person. 
 
Testing strategy — 
 
The use of an appropriate HIV test or combination of HIV tests for identifying 
positive specimens. The choice of testing strategy used is based on the objective of the test, 
the sensitivity and specificity of the test, and HIV prevalence in the population being tested.
 
Window period — 
 
The period of time following exposure and infection with HIV and the 
generation of detectable antibodies by the infected person.
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Executive Summary
 
Ensuring the quality of  HIV testing in support of prevention and care efforts has been identi-
fied as a priority by the U.S. Centers for Disease Control and Prevention (CDC) and the World
Health Organization/African Regional Office (WHO/AFRO). Rapid/simple HIV tests are marketed
widely, and promoted for use by a variety of HIV/AIDS prevention strategies such as voluntary
counseling and testing (VCT) and prevention of mother to child transmission (MTCT). It is vitally
important that before these and other HIV assays are utilized, countries evaluate the performance
of each assay to determine its performance characteristics and suitability for use within a given
country setting. This evaluation is considered a critical aspect of assuring the quality of test
results, and all countries must make this a priority.
This document is intended to provide those involved with planning or conducting any aspect
of test evaluations practical guidance for developing country-specific protocols for conducting
evaluations of HIV EIA and rapid/simple test methods.   As test evaluations require both time and
resources, specific guidance is given on the rationale and justification for evaluating new tests,
issues to consider when planning an evaluation, and projected timeline for an evaluation.
Detailed descriptions of phases of the evaluation quality assurance, evaluation materials, e.g.,
specimens, and laboratory safety precautions are also presented in this document. 
 Background —
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1.0 Background
 
1.1 Serodiagnosis of HIV
 
Africa is the continent most affected with human immunodeficiency virus (HIV) epi-
demic: of the estimated 40 million persons infected with HIV in the world by the year 2001, 28
million live in Africa [1].  HIV antibody testing is critical for controlling the epidemic because it
is the critical entry point for both prevention and care efforts for HIV/AIDS.   For instance, short-
course regimen of antiviral therapeutics administered to HIV-infected pregnant women reduces
rates of transmission of HIV-1 from infected mothers to infants by 38% to 50% [2,3, 4, 5, 6]. Also,
cotrimoxazole administered together with standard tuberculosis therapy reduces mortality and
morbidity by 40 - 45% among HIV- infected tuberculosis patients [7]. For HIV-infected persons to
benefit from such therapies, they must be diagnosed appropriately. Serologic diagnosis of HIV
infection is based on a multi-test algorithm for detecting antibodies to HIV.  Screening tests pro-
vide presumptive identification of specimens that contain antibody to HIV.  These enzyme immu-
nosorbent assays (EIAs) or simple/rapid immuno-diagnostics are selected for their high sensitivity
of detecting antibodies to HIV.  Supplemental or confirmatory tests, such as Western blot (WB),
can be used to confirm infection in samples that are initially reactive on conventional EIAs.
Alternatively, repetitive testing incorporating EIAs or rapid tests selected for their specificity may
be used to confirm whether specimens found to be reactive for HIV antibodies with a particular
screening test are specific to HIV. For practical purposes, resource-poor settings depend heavily
on EIA and rapid tests for screening and confirmation.
 
1.2 EIAs
 
EIAs are the most widely used screening tests because of their suitability for analyzing
large numbers of specimens, particularly in blood screening centers.  Since 1985, EIAs have pro-
gressed considerably from first to fourth generation assays: first generation assays were based on
purified HIV whole viral lysates, however, sensitivity and specificity of these assays were poor;
second generation assays used HIV-recombinant proteins and/or synthetic peptides, which
enabled the production of assays capable of detecting HIV-1 and HIV-2. The assays had improved
specificity, although their  overall sensitivity was similar to that of first-generation assays. Third-
generation assays used the solid phase coated with recombinant antigens and /or peptides and
similar recombinant antigens and peptides conjugated to a detection enzyme or hapten that could
detect HIV-specific antibodies bound to a solid phase. These assays could detect immunoglobulin
M, early antibodies to HIV, in addition to IgG, thus resulting in a reduction of the seroconversion
window. Fourth generation assays are very similar to third-generations tests but have the ability
to detect simultaneously HIV antibodies and antigens. Typical fourth-generation EIAs incorporate
cocktails of HIV-1 group M (HIV-1 p24, HIV-1 gp160), HIV-1 group O, and HIV-2 antigens (HIV-
2 env peptide). Furthermore, third and fourth-generation assays are able to detect IgM and IgG
antibodies to both HIV-1 and HIV-2. These assays may reduce the 2-4 week time period or “win-
dow period” of detecting HIV antibodies.
 
1.3 Rapid/Simple assays
 
Simple, instrument-free assays are also available and are now widely used in Africa. They
include agglutination, immunofiltration, and immunochromatographic assays. The appearance of
a colored dot or line, or an agglutination pattern indicates a positive result.  Most of these tests
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can be performed in less than 20 minutes, and are therefore called simple/rapid assays. Some sim-
ple tests, such as agglutination assays, are less rapid and may require about 30 minutes to 2 hours
to be completed. In general, these rapid/simple tests are most suitable for use in settings that have
limited facilities and process fewer than 100 samples per day.
 
1.4 Importance of rapid/simple assays
 
Although EIA–based serodiagnostic algorithms are highly cost effective, their application
in resource-poor settings is limited by several factors. They require well-trained personnel, need a
consistent supply of electricity, and maintenance and cost of most equipment.  Rapid assays have
high sensitivity and specificity and perform as well as EIAs on specimens from persons serocon-
verting for non-B HIV-1 subtypes [8]. Rapid enzyme assays circumvent the issue of low rates of
return for serologic results associated with EIA-based testing algorithms because results can be
delivered on the same day. In addition, their performance has improved considerably, and some
do not require reconstitution of reagents or refrigeration; thus, making them very suitable for use
in resource limited settings and hard to reach populations. Practical applications for the use of
simple/rapid assays are in settings such as Voluntary Counseling and Testing (VCT) and Preven-
tion of Mother to Child Transmission (PMTCT) programs.  Studies have shown that using rapid
assay testing algorithms result in remarkable increase in the number of HIV-positive women
identified as eligible to receive the short-course therapy that reduces mother-to-child transmis-
sion of HIV [9].
 
1.5 Synopsis of HIV Testing 
 
A testing algorithm for serologic diagnosis of HIV-infection is the sequence in which
assays are performed to detect HIV antibody  in a body fluid. The most common referenced test-
ing algorithm employs an EIA to screen specimens with those found to be positive then con-
firmed by WB testing. This so-called conventional algorithm has several limitations:
• WB is expensive and requires technical expertise
• WB often yields indeterminate results with certain types of specimens with uncertain
diagnostic significance, e.g.,  hyperimmunoglobulinemia specimens 
• Both ELISA and WB are time consuming and require a well-equipped laboratory
infrastructure
Several alternative testing algorithms exist for the serologic diagnosis of HIV infection
that are  based on a combination of screening assays, without using WB. In a parallel testing
algorithm, sera are simultaneously tested by two assays.  In the serial algorithm all specimens are
tested by a first test that is highly sensitive. Specimens are considered as true negative if they
react negatively in the first test. Specimens that are reactive in this assay are retested by a second
EIA that has a high specificity.   Parallel testing algorithms are often used in the clinic setting,
such as with rapid assays using whole blood fingerstick specimens, to avoid requesting a second
specimen from the client when the first test is HIV reactive.   Serial algorithms may be more cost
effective and convenient when sufficient specimen, such as with a venipuncture, is available to
perform additional tests when the initial test is HIV reactive.  
These algorithms maintain accuracy and minimize cost.  Most of these algorithms have
been evaluated in field conditions in Africa and found to be highly effective.   Regardless of the
testing algorithm (Appendix A), the first test must be highly sensitive and the second should be
highly specific.
 Background —
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1.5.1 WHO/UNAIDS testing strategies
 
In considering both serial and parallel testing algorithms, WHO and UNAIDS have recom-
mended three testing strategies (figure 1).   Criteria for choosing the appropriate HIV testing
strategy (Appendix B) include: 
1. Objective of the test (diagnosis, surveillance, blood safety, or research),
2. Sensitivity and specificity of the test(s) being used, and 
3. HIV prevalence in the population being tested
Potential testing strategies based on data from several countries can be found in Appendix
C.    Information on the manufacturers of rapid test kits can be found in Appendix D. 
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Figure 1.  Schematic representation of the WHO/UNAIDS HIV testing strategies
Strategy I: Strategy II: Strategy III:
 
Transfusion/transplant safety Surveillance — Diagnosis — Prevalence <10%
Surveillance — Prevalence >10% Diagnosis - 
Prevalence > 10%, asymptomatic
Prevalence < 30%, symptomatic
A1 A1A1
A1+
Consider
positive2
A1–
Report
negative3
  A1+
A2
A1–
Report
negative3
A1–
Report
negative3
  A1+
A2
A1+ A2+
Report
positive4
A1+ A2– A1+ A2+ A1+ A2–
Repeat A1and A2 Repeat A1and A2
A1+
A2+
Report
positive4
A1–
A2–
Report
negative3
A1+
A2–
Consider
indeterminate5
A1+
A2+
A1+
A2–
A1– A2–
Report
negative3
A3
A1+ A2+ A3+
A1+ A2+ A3– or
A1+ A2– A3+ A1+ A2– A3–
Report
positive4
Consider
indeterminate5
High risk Low risk
Consider
indeterminate5
Consider
negative6
1 Assay A1, A2, A3 represent 3 different assays.
2 Such a result is not adequate for diagnostic
purposes; use strategies II or III.  Whatever the
final diagnosis, donations which were initially
reactive should not be used for transfusions or
transplants.
3 Report:  result may be reported.
4 For newly diagnosed individuals, a positive
result should be confirmed on a second sample.
5 Testing should be repeated on a second sample
taken after 14 days
6 Result is considered negative in the absence of
any risk of HIV infection.
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2.0 Rational and Justifications for 
Conducting Test Evaluations
 
2.1 Rationale for evaluating assays in Africa  
 
HIV testing algorithms involving the use of supplemental assays such as Western blot
(WB) or line immunoassay (LIAs) to confirm infection in samples that are initially reactive on EIA
conventional algorithms are still impractical in most African countries due to the high cost of the
supplemental assays, long turnaround time, and difficulties related to interpreting WB and EIA
strips. To circumvent these limitations, reliable and less expensive HIV serodiagnostic algorithms
have been evaluated and shown to be as sensitive and specific as the conventional algorithm [10,
11, 12, 13, 14, 15]. For the testing algorithms to be effective, assays employed in them must be
highly sensitive and specific within the context of the HIV situation in each country.
A high degree of genetic diversity exists in several countries in Africa [16]. For instance,
HIV-1 circulating recombinant form (CRF_02), and HIV-2 predominate the epidemic in West
Africa. In Central Africa, a mixture of subtypes, CRFs, group O and N exists. In East Africa, sub-
types A, C, and D predominate; and in Southern Africa, subtype C is most frequent. Although
rapid tests continue to improve like EIAs, antigens used for these assays were originally derived
from HIV-1 subtype B viruses. Thus, the existence of newly identified aberrant HIV variants in
Africa coupled with the high degree of genetic diversity of HIV has historically posed a challenge,
especially for persons during early seroconversion. Indeed, some studies have shown a signifi-
cantly lower sensitivity of some screening assays to detect non-B subtypes antibodies during
seroconversion [17].  Moreover, several EIAs were withdrawn from circulation when it was shown
that some variants of HIV-1 group O viruses were missed by these assays. 
 
2.2 Justification for evaluating new HIV tests kits
 
There are many reasons to perform evaluations of HIV tests.  Many countries are perform-
ing evaluations to determine an algorithm of simple rapid tests that can be used at the point-of-
service for VCT, PMTCT, and surveillance.   If a country has previously conducted evaluations and
has selected an algorithm of rapid tests that performs adequately, then there must be compelling
reasons for considering evaluating additional tests.  There is often much demand from manufac-
turers or donors to evaluate specific tests for use within a country.  Due to the number of kits
appearing on the market, a preliminary review of available performance data cannot be over
emphasized.  Data are often available regionally that permit a presumptive determination of the
assay’s sensitivity and specificity, reducing the need to evaluate numerous  tests. As a conse-
quence of available data, the decision may be made to tailor an evaluation to focus solely on the
potential implications of integrating the product into an existing algorithm.  An evaluation of
testing algorithms requires time and resources, and each country must determine the potential
advantages of a test (s) before deciding to perform a formal evaluation.
• Is there evidence from published studies that indicate the test has greatly improved
performance characteristics? 
• Is the test(s) much simpler to perform?
• Is the test(s) more stable to ship and store? 
• Is there a significantly reduced cost with evidence that the proposed cost will not
increase significantly after implementation? 
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In many cases there may be no demonstrable improvement gained in a full-scale evalua-
tion of a new product, either because evidence is already sufficient to determine its efficacy or
there is no demonstrable need.  For example, if a test or algorithm has proven efficacy (Se and
Sp) within the immediate region, then a country may decide to start the evaluation in the point of
service (POS) setting rather than an initial full scale laboratory-based evaluation.  Other circum-
stances requiring a limited evaluation at the POS include revising the order of tests within an
approved algorithm or replacing a single test within  the algorithm. 
Countries should resist pressures to evaluate products solely for in country marketing
concerns.  For tests that will be evaluated in-country, every effort should be made to allow man-
ufacturers or marketers to bear the costs of evaluating new tests, as evaluations consume a con-
siderable amount of time and precious resources.  Adopting new tests without adequate
evaluation should NOT be considered an option.  Doing so will compromise the integrity of the
testing facility, personnel, and quality of reported results to the patient and/or client.
 Laboratory Quality Assurance (QA) and Safety —
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3.0 Laboratory Quality Assurance (QA) and Safety
 
3.1 Importance of Quality Assurance
 
Laboratory Quality Assurance (QA) is defined as planned and systematic activities to pro-
vide adequate confidence that requirements for quality will be met.  It is critical that each facility
performing laboratory testing establishes and implements a QA program to monitor and evaluate
laboratory functions and services throughout the total testing process.  The total testing process is
comprised of the pre-analytical, analytical, and post-analytical phases of laboratory testing.  Spe-
cific activities (although not all inclusive) of the total testing process related to evaluations are
outlined below.  
 
Pre-Analytical phase encompasses the following components:
 
• Test request
• Test selection
• Trained testing personnel
• Patient/client preparation
• Specimen collection, labeling, and transport 
 
Analytical Phase
 
• Specimen processing and storage
• Reagent preparation
• Preventative maintenance / Equipment checks
• Quality control
• Test performance
• Proficiency Testing / External Quality Assessment
• Specimen storage
 
Post-analytical Phase
 
• Reviewing quality control
• Transcribing results
• Reporting results
• Interpreting results 
• Maintaining records 
Written polices and procedures for each activity  will assist in continually assessing the
total testing process for areas needing improvement, in identifying problems, and in having
defined mechanisms to prevent the reoccurrence of problems.  A successful QA program will need
the support of the National Reference Lab and requirements should be rigorously complied with
to ensure the accuracy of the results from the evaluation and all other assays.  Comprehensive QA
program guidance is beyond the scope of this document and can be found in an internationally
accepted quality management document, e.g., ISO 15189 –Quality Laboratory Management.   
 8  — Laboratory Quality Assurance (QA) and Safety
 
Guidelines for Appropriate Evaluations of 
HIV Testing Technologies in Africa
 
3.2 Quality control (QC)
 
Quality control (QC) refers to those measures that are taken to monitor the quality of the
assay itself.  QC may include the assay of samples/materials with known test results to verify the
procedure itself is working properly.  When QC materials analyzed daily produce acceptable
results, and all other testing conditions have been met, then the results of the samples being ana-
lyzed may be considered acceptable. 
 
3.3 External Quality Assessment (EQA) / Proficiency Testing   
 
Every testing facility must at any time be ready to demonstrate and document its compe-
tence in performing HIV serology that is carried out as part of its routine services.  External Qual-
ity Assessment (EQA) is one component of a laboratory QA program.  The focus of EQA is on
identifying laboratories or testing sites and technicians exhibiting poor performance. There are
three methods that can be used as part of a program to evaluate laboratory performance:
• On-site Evaluation
• Proficiency Testing
• Blinded Rechecking
The choices for which type of EQA program to implement will depend on both the avail-
able resources and the ability to obtain additional resources as needed to support the EQA pro-
gram.
Additional information on proficiency testing and the use of Dried Blood Spots (DBS) as a
form of EQA are highlighted in section 5.6.2 (Phase III: Implementation and Monitoring of Test
Performance - EQA).
 
3.4 Safety Precautions
 
Each laboratory or testing site must follow Universal (Standard) Precautions designed to
prevent transmission of HIV, hepatitis B virus (HBV), and other bloodborne pathogens.  When
laboratories adhere to  universal precautions, blood and certain body fluids of all patients are
considered potentially infectious for HIV, HBV and other bloodborne pathogens. Refer to Appen-
dix E for safety rules [18] that should be followed when working in the laboratory.
 Planning an Evaluation —
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4.0 Planning an Evaluation 
 
4.1 Responsibilities of a National Reference Laboratory
 
The Ministry of Health (MOH) and the national authority responsible for HIV/AIDS con-
trol, e.g., National AIDS Control Program (NACP), should designate a National Reference Labora-
tory (NRL) or other recognized laboratory in the country that is assigned overall responsibility for
coordinating and conducting evaluations of HIV tests.  The NRL should work closely with the
National AIDS control authorities in each country to ensure coordination of efforts and activities.
Each country will need to evaluate its support structure and available resources in order to deter-
mine the most effective way to conduct the evaluations.
 
Responsibilities of the NRL
 
The NRL should:
• Be mandated by the government to either coordinate or perform test evaluations
• Have sufficient resources to conduct  or oversee country test evaluations
• Strive to adhere to internationally recognized quality standards, e.g., ISO 15189;
Quality management in the medical laboratory, UK Standards for the Medical Labora-
tory, etc.
• Advise the government about making recommendations and setting policy
• Maintain existing reference methods, such as EIA, and perform or provide access to
additional reference methods, e.g., WB, PCR, etc.
• Support the NACP and other laboratories meet the increased need for simple/rapid
tests in an environment of decentralization 
• Establish and oversee implementation of a national QA program for HIV testing
• Write standard operating procedures for distribution to all testing sites
• Characterize and  maintain evaluation and reference panels
 
4.2 Program coordination 
 
Evaluation of HIV test kits should always be coordinated with the NACP and any other
organizations that will be using the tests and/or results.  Program staff should  help pre-select test
methods, especially if rapid tests are being evaluated for use at POS locations and non-laboratory
staff might perform tests.   Shared decisions in the planning stages might include the costs of
tests, test result reporting, ease of use, storage, data-sharing mechanisms, in addition to test per-
formance characteristics.
 
4.3 Funding considerations
 
Evaluation of tests will require funding over and above the normal operating costs of per-
forming diagnostic testing.  One component of planning involves developing an itemized budget
for each additional cost and ensuring that funds are available before initiating an evaluation.
The itemized budget should include estimates for the additional test kits, supplies, any necessary
equipment for testing or storage, transport of specimens during field-testing, and any additional
staff costs (Appendix  - F). 
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4.4 Test Selection Criteria for Country-level Evaluations
 
Having appropriate justification for conducting test evaluations, guidelines for selecting
assays for evaluation include:
• Assays that  have been previously reviewed by WHO, CDC or other independent inter-
national organizations with relevant expertise
• Published regional test performance data from:
Journal Publications 
WHO/UNAIDS
Manufacturer-provided data
Websites:   WHO/AFRO – www.AFRO.WHO.INT
                CDC – http://www.phppo.cdc.gov/DLS/default.asp
• Documented ability of the test to detect HIV-1 (group M and O) and HIV-2
• Documented ability to detect IgG and IgM antibodies
• Cost per test and possibility for bulk purchase
• Storage requirements
• Equipment and maintenance requirement
• Required technical skill
• Ease of use; Simplicity of test procedure
• Experience with the assay(s)
• Availability
• Shelf-life and robustness
• Service and trouble-shooting provided locally by manufacturers
• Laboratory infrastructure
 
4.5 Overview of Planning Activities and Timeline 
 
The following list of activities and timeline (figure # 2) represents a typical process for
conducting laboratory test evaluations.  Details of each phase of the evaluation are explained in
detail in section 5.0 (Conducting the Evaluation).   Sample contents of and evaluation protocol
can be found in Appendix G. 
• Determine capacity to conduct evaluations
• List kits available in country and/or kits approached to evaluate 
• Conduct literature and data review
• Conduct situation analysis
• Conduct needs analysis
Select kits worth assessing
Conduct consensus meetings to gain cooperation of stakeholders
• Develop Evaluation Protocol
 Planning an Evaluation —
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• Obtain ethics clearance
• Procure kits, supplies, etc.
• Conduct Training
Clinic and lab staff
• Pilot test logistics of plan
• Implement phase I
• Evaluate phase I
• Analyze phase I data
• Decide which kits to use in phase II / Determine algorithm
• Publish phase I findings
• Select sites for phase II
• Implement phase II
• Evaluate phase II
• Analyze phase II findings
• Decide which kits/ algorithm to use in the country/setting
• Publish phase II findings
• Implement phase III = ongoing monitoring
Build capacity for this during phase I and II trials
 
4.6 Technical Training Requirements:
 
Training should be provided for laboratory and POS testing staff, ideally at the site in
which testing will occur, rather than at a centralized venue.  Training should also be provided for
assessors responsible for monitoring EQA activities of testing sites.
Every effort should be made to ensure continuity of training throughout the evaluation
process through the use of documented processes and procedures.  In addition to performance of
assays, the training should include QA, QC, data management, and laboratory safety.  Organizers
of the training should ensure availability of training venue, test kits, supplies and samples.    
Expansion of training activities is further addressed in section 5.6.1 (Phase III – Training
Requirements).
 Planning an Evaluation —
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5.0 Conducting the Evaluation
 
5.1 Overview evaluation phases
 
Evaluation of HIV testing performance is an ongoing process that begins prior to imple-
mentation of testing and continues after tests have been implemented in the field.  The evaluation
process is divided into three phases. Although these phases can apply to evaluation of any  HIV
tests using serum, plasma, saliva, or whole blood, for the purposes of this document, emphasis is
focused on evaluating rapid test methods that can be used in the POS setting with whole blood
specimens.  Evaluation of rapid tests for use in the POS setting is usually more complex than
evaluations of standard EIA formats that can be tested in parallel with the existing EIA in a labo-
ratory setting.  
Phase I is a laboratory-based evaluation to provide preliminary results on test perfor-
mance characteristics (Se, Sp) on the same set of samples.  Having evaluated the same sample set
that may consist of 4-7 rapid tests, an algorithm of 2-3 tests may then be proposed based on the
performance of the combination of test methods.
Phase II involves evaluation of the selected algorithm under field conditions that may
include test performance and interpretation by non-laboratory clinic staff.   Phase II is often
referred to as the field trials, and typically is conducted in at least 2-3 POS sites.  Tests under
evaluation in this phase should be performed in the same manner in which it is to be used, e.g.,
finger stick specimens.
Phase III represents ongoing evaluation of performance through EQA programs that not
only monitor the performance of individual clinic and/or staff, but also provide aggregate data
for ongoing assessment of test performance. 
 
5.2 Objectives of Evaluation Phases
 
Objectives of Phase I:  
 
• Provide preliminary performance characteristics on tests under evaluation
• Develop a panel of well-characterized serum for future use
• Review performance of each test combination to develop 2-3 test algorithm
 
Objectives of Phase II:
 
• Evaluate the performance of the 2-3 test algorithm in the POS setting
• Perform a demonstration study in selected sites and conditions that will provide a
reasonable/reliable indication of how the testing methods and algorithm will perform
when implementation is expanded to multiple sites through the country
 
Objectives of Phase III:
 
• Ensure each new testing site has appropriate training and preliminary observation of
performance prior to reporting results
• Assess clinic/ staff performance through EQA  
• Monitor aggregate test performance
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5.3 Evaluation Scenarios
 
Diagram 1 is a  scenario in which the NRL is preparing for the evaluation by collecting,
characterizing and storing serum specimens for later evaluation.  This allows the NRL to collect
and store approximately 500 specimens over a period of weeks to months and then separately
evaluate several new tests in a few days.    
Diagram 1
Collect serum, evaluate EIA &
simple/rapid tests at later date,
validate with whole blood
Collect,
characterize,
store serum
Phase I Phase I
Evaluate tests
Select 2–3 test
algorithm
Verify with whole
blood (if applicable)
NRL or
blood center
Pilot test algoithm
in testing sites
Ongoing evaluation
of algorithm
EQA & Monitoring
POSPhase II
National
Implementation
Phase III
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Advantages
 
• The NRL can pick and choose the appropriate number of positive and negative speci-
mens for evaluating tests from all the specimens received over  time.
• This scenario avoids unnecessary testing of excess negatives or specimens that cannot
be characterized with the tests that are under evaluation.  
• The evaluation panel can be collected without making major changes to the labora-
tory workload. 
• Multiple tests can be evaluated with stored sera in a short time (e.g., <1 week).
 
Disadvantages
 
• Evaluation with stored serum may be sub-optimal, as additional requirements must be
met for sample preparation and storage, and different performance characteristics
may result in testing fresh sera compared with testing stored sera.
• Different performance characteristics may be observed with whole blood after initial
evaluation with serum.
• For whole blood-based rapid tests, an additional step using whole blood to provide
preliminary validation data of performance characteristics is required before imple-
menting phase II. 
• The laboratory must have sufficient resources to meet quality standards for storing
specimens.  At a minimum, a subset of stored specimens should be retested to ensure
validity of earlier results.  If any deviation is found in the subset of re-tested speci-
mens, then all stored samples must be retested.  
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Diagram 2 is a scenario in which the tests being evaluated are performed concurrently
with standard test methods.   This scenario still represents the use of serum due to limited avail-
ability and logistical difficulty in transporting whole blood to the NRL.  Since the tests are per-
formed concurrently, less is required for managing the storage and retrieval of specimens.
Diagram 2
Prospective evaluation of
EIA & simple/rapid tests
with characterization of serum or whole blood
Test and characterize
serum with concurrent
test evaluation
Phase I NRL
Select 2–3 test
algorithm
Validate with
whole blood
if applicable
NRL or
blood center
Pilot test algoithm
in testing sites
Ongoing evaluation
of algorithm
EQA & Monitoring
POSPhase II
National
Implementation
Phase III
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Advantages
 
• By testing fresh sera, the NRL avoids the necessity of previous rigid requirements for
aliquoting and storing specimens prior to beginning the evaluation.
• Since evaluation tests are performed concurrently, there will be earlier indications of
unacceptable performance. Given these early indicators, one may stop evaluation of
tests as soon as a statistically significant sample size is reached. 
 
Disadvantages
 
• In a lower prevalence setting, the laboratory may have to perform preliminary tests
on excess negatives; leading to an increase in the length of time before phase I is
completed. 
• Evaluation with stored sera may be sub-optimal for whole blood-based rapid tests.
There is the possibility of observing different performance characteristics when used
with whole blood in phase II.
• For whole blood-based rapid tests, an additional step is required to provide prelimi-
nary validation of performance characteristics data before implementing phase II. 
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Diagram 3 is a scenario in which the laboratory can perform a concurrent prospective
evaluation using whole blood prior to characterizing the serum with the gold standard methods.
This type of evaluation is possible when there are laboratory resources to perform 3-5 tests in a
clinic setting, such as blood center, where whole blood is immediately available.
Diagram 3
Prospective evaluation of
simple/rapid tests whole blood & serum
characterized in same or different laboratory
Evaluate tests with
whole blood
Phase I
NRL
(if separatelabs/locations)
Select 2–3 test
algorithm
Pilot test algoithm
in testing sites
Ongoing evaluation
of algorithm
EQA & Monitoring
POSPhase II
National
Implementation
Phase III
NRL, University, Blood Center,
POS with associated lab
characterize serum
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Advantages
 
• Using whole blood to evaluate rapid tests that will be used in POS settings with whole
blood is the best method in directly determining the performance characteristics and
selecting an algorithm
• This scenario negates the need for an additional step of validating using  whole blood
specimens
 
Disadvantages
 
• The whole blood is often retrieved from a venous sample and may not mimic all the
aspects of test performance when used with a fingerstick specimen
• Performing a concurrent evaluation of several tests with whole blood may be logisti-
cally difficult due to requiring a laboratory in the POS setting
• Performing 3-4 tests concurrently directly from fingersticks may be logistically diffi-
cult, particularly if non-lab staff are performing tests
 
5.4 Phase I:  Laboratory Evaluation
 
5.4.1 Use of Stored Serum 
 
Fresh sera are the preferred specimens for evaluation of serum-based tests and prelimi-
nary evaluation of whole blood tests when whole blood is not immediately available.  If sera are
frozen before the evaluation, there should be some standards and practices to ensure that the
quality of the thawed serum has not been impaired by freeze/thawing, contamination, excess par-
ticulate matter, etc.  The sera should be aliquoted in separate vials to avoid multiple freezing/
thawing.  For monitoring the quality of frozen storage, a percentage of specimens should be
retested with standard tests prior to performing the evaluation to ensure that test results do not
change.  
 
5.4.2 Sample Size
 
A test evaluation should include a minimum of approximately 200 HIV-positive and 200
HIV-negative specimens to provide 95% confidence intervals of less than ± 2% for both the esti-
mated sensitivity and specificity.  Lower numbers of HIV-positive and HIV negatives specimens
may be used, but this will increase the confidence interval for sensitivity and specificity.   The
total number of specimens included in the evaluation will depend on whether the HIV reactivity
of the specimens is known prior to evaluating the test.    In a prospective evaluation, such as
using whole blood in the clinic setting where the HIV reactivity is unknown, the evaluation
would be performed until a minimum of 200 positives are obtained.   For instance, in a setting
with 20% prevalence this might require testing upwards of 1000 specimens until 200 positives are
obtained (Appendix H).  In a laboratory-based evaluation where the HIV reactivity of specimens
is known, such as with previously tested and stored serum or plasma specimens, it is preferable
from a cost perspective to select 200 HIV-positives and 200 HIV- negatives.    
When a whole blood or serum-based rapid/simple test is initially evaluated in phase 1
with serum, then an additional validation step is required to provide some reassurance that the
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performance in whole blood is similar to that obtained in serum before initiating a more exten-
sive evaluation in Phase 2.   This assessment does not need to be as extensive as the serum-based
evaluation,  The test methods representing a 2-3 test algorithm should be validated with 50-100
whole blood specimens (containing a minimum of 20 positives).
 
5.4.3 Sample Population
 
Selecting the sample population for a test evaluation will include several considerations.
Although there are considerations of having a sample that is representative of the various areas
of the country, this may not be feasible in phase I when the NRL is limited to available specimens.
If specific concerns exist about how  HIV-1 and HIV-2 or specific subtypes are distributed, these
might be addressed by selected specimens in a panel.  In most instances the primary goal should
be selecting a population with a high prevalence of infection to obtain a sufficient number of
positives.  
 
5.5 Phase II – Field Evaluation / Pilot testing
 
5.5.1 Number of Sites
 
In Phase II, the selecting testing sites from different areas of the country should  be bal-
anced with the need and logistics of monitoring on-site testing and transport of specimens to the
NRL for characterization by the gold standard method.  At a minimum, 2-3 sites should be con-
sidered for inclusion in Phase II of the evaluation.  Some larger countries may need to consider
up to 4-5 sites that are implemented sequentially to allow for training at each site.  Managing the
logistics of transporting specimens and reporting may be difficult with more than 3 sites. 
 
5.5.2 Sample Size
 
The same sample size for Phase II evaluation should be used as in phase I.  This will
require finding a sufficient number of field test sites with high prevalence to obtain the minimum
of 200 positives distributed across all sites.
 
5.5.3 Sample Population 
 
If a country has specific concerns about having a representative population for test eval-
uation, these should be addressed through the selection of testing sites in Phase II.  The primary
concern should be about representative testing conditions.
 
5.6 Phase III – Implementation and Monitoring
 
5.6.1 Training Requirements
 
When tests and algorithms have been evaluated in phase II and considered acceptable,
there is continued need to provide training and support for systematic implementation in addi-
tional sites.  The NRL and NAP must develop a plan than involves training and evaluation of staff
at new sites prior to reporting results to patients.   In many cases, implementation will involve
merging testing practices, evaluation, and quality assessment into counseling programs and set-
tings.
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Training all staff, laboratory or non-laboratory, who will perform the test(s) is a necessary
and important prerequisite to expanding the testing sites.   Training topics should include at a
minimum, test performance, quality control, safety, and also include some measure of test perfor-
mance with standard competency proficiency panels established by the NRL.  Successful partici-
pants should receive a certificate acknowledging their competency.   The certificate, however,
should recognize that the training and competency are limited to specific tests performed during
the training.  
Every new testing site should receive a laboratory visit that combines training and evalu-
ation by observation.   This visit should be a standard component of implementation and occur
before any patient test results are reported.   Each site should be provided with SOPs for testing
either during training or as part of the initial visit.   When appropriate, the NRL should provide
control materials for the specific tests.     
 
Initial evaluation of the pInitial evaluation of the performance of testing personnel
 
The performance of individuals at each site should be evaluated before  results are
reported.   For rapid tests, this should involve taking an additional venous sample on the first 50-
100 patients and comparing the rapid test results obtained in the POS with the standard EIA
results.  The results reported to the patient/client should be based on results from the standard
EIA.
 
5.6.2 EQA
 
There should be at least one or more methods available to assess the quality of testing
within a country.  This should include every NRL establishing a program for monitoring different
manufactured lots of tests kits that are received/purchased by the country.  This will require using
a standard reference panel to assess lot-to-lot performance for each individual test.  Special con-
sideration should be given to including weak positives for adequately assessing any lot-to-lot
variations in test sensitivity.
5.6.2.1 Onsite Evaluation
External quality assessment programs should provide onsite evaluation of each testing
site in addition to methods that will assess testing performance. Having onsite evaluation is nec-
essary to review QC, record keeping, and observation of test performance.  Additionally, this eval-
uation is an opportunity to directly administer a proficiency test to each individual performing
testing during the visit.  A program of onsite evaluation should include a standard checklist of
laboratory indicators and evaluators should be trained to perform consistent reviews of laborato-
ries and other POS sites.  Standard checklists and evaluation methods allow for collecting and
comparing  consistent information from multiple sites. 
5.6.2.2 Proficiency Testing
Proficiency testing (PT) is the most common form of EQA and involves development of
specimen panels by the NRL for distributing to POS sites.   Laboratories administering PT panels
should strive to adhere to international guidelines, e.g., ISO Guide 43. There are standard methods
available to develop PT samples and might be the easiest type of program for implementation at
sites where serum-based tests are performed.   The limitations of PT are that it usually involves
only a few  specimens and the test results may not represent the routine test performance.  This
may be due in part to the greater care in handling PT specimens.
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5.6.2.3 Blinded Rechecking
Retesting  selected  specimens in a reference/referral laboratory may also assess the qual-
ity of testing.   This can be accomplished by forwarding all positive and 10% of negative speci-
mens for standard EIAs when a venous specimen is available.   Another systematic sampling
method may be considered to reduce the potential bias of selecting test specimens for referral.  
5.6.2.4 Dried Blood Spots (DBS)
The use of dried blood spots (DBS) is one method that is being developed as EQA for
whole blood tests where it may be impractical to refer specimens for additional testing or where
there is limited or no access to serum PT specimens for monitoring test performance.  The DBS are
collected at the time of patient testing (e.g. fingerstick) on filter paper and easily transported to a
reference laboratory.  The use of DBS will require a reference laboratory that has demonstrated
proficiency with eluting the DBS specimens and performing standard EIA methods.  Additional
concerns include the logistics and methods of collecting DBS in the testing protocol.   Although a
statistical sample of specimens re-tested by DBS based on testing volume may be desirable, this
may be difficult to implement in the flow of testing and counseling of patients.  Additionally,
testing a percentage of specimens, such as 10% may be problematic.  Countries may consider ran-
dom sampling of DBS such as bimonthly, or at a given time or day. Further development of DBS
protocols, proficiency testing and EQA guidelines are necessary to assist with the expansion and
monitoring of rapid testing.  
5.6.3 Remediation / Corrective Measures
When deficiencies are noted during on-site visits, corrective measures should be taken to
ensure the quality of results.  This may include additional training and discontinuation of ser-
vices. 
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6.0 Evaluation Materials
6.1 Types of evaluation materials
These guidelines describe several types of evaluation panels that may differ by the com-
position of negatives and positives, and by degree of characterization.  Specimen library is a term
given to the source or collection of all specimens that may be selected and retrieved for evalua-
tion purposes.   In some instances, this might represent a large collection of stored sera from
which a set of positives and negatives is selected and retested for inclusion in the evaluation.  The
specimen library could also represent all fresh specimens tested in the laboratory where only a
subset of specimens is selected for evaluation.  
The evaluation panel consists of those specimens that are tested by the gold standard
method and evaluation test methods and included in calculating the sensitivity and specificity for
individual tests and algorithms.  The evaluation panel should usually consist at a minimum of
400-500 total specimens including at least 200 positives.
A laboratory may also have available several special reference panels.  These panels may
represent a collection of difficult or unusual specimens that provide a unique challenge to the
tests being evaluated. Samples from uninfected and infected persons, which represent unusual
screening results and have been further tested to resolve serostatus, may be used in the panel as
challenges to the sensitivity and specificity of an assay under evaluation.  Because the sensitivity
of some antibody tests is less for sera collected early in HIV infection for persons infected with
non-B subtypes, it is important to evaluate the assays on panels containing specimens from per-
sons recently infected with the HIV-1 or HIV-2 subtypes circulating in the country.  
Each specimen in the reference panel should be tested with multiple EIAs and positives
confirmed with Western Blot and when possible, additional tests including p24, PCR, genotype,
etc. 
Because of repetitive use of reference panels during Phase II and Phase III, stability and
storage of samples are critical.  Samples should be aliquoted into storage vials and preferably fro-
zen at –70o (minimum standard is –20o when molecular procedures are not used). 
6.2 Specimen Collection and Handling
6.2.1 Specimen Collection
Plasma
Collect up to 10 ml of blood from the patient’s vein into a sterile anticoagulated tube.
Choice of anticoagulant should be appropriate to the test being evaluated according to the manu-
facturer’s insert.  Using  an evacuated blood collection system is recommended for safety. The
blood drawn is immediately mixed by gently inverting the tube 10 times.  Shaking should be
avoided to prevent hemolysis.  
The specimen should be centrifuged at 300-400g for 10 minutes to separate the plasma.
After centrifugation, the separated plasma should be withdrawn using a clean pipette and trans-
ferred to a storage tube.  Ideally, specimens are prepared for storage in 0.5ml aliquots.
Serum
Collect up to 10 ml of blood from the patient’s vein into a sterile serum separation tube,
preferably an evacuated blood collection tube without anticoagulants.  Again, shaking should be
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avoided to prevent hemolysis. Let the blood stand for 20-30 minutes at room temperature to
allow for clot formation.  Serum can be separated from the clot by centrifugation at 300-400 g
for 10 minutes.  Alternatively, gently draw the serum off the clot using a sterile pipette. The
serum can be subsequently clarified further by centrifugation at a remote site.  Specimens should
be prepared for storage in 0.5 ml aliquots.
Whole Blood
Collect up to 10 ml of blood from the patient’s vein into a sterile tube containing an anti-
coagulant.  Again, choice of anticoagulant should follow test manufacturer’s recommendations.
Immediately draw off sufficient quantities of whole blood to run the tests under evaluation.  The
remaining blood should be used for preparing  of plasma as described above. 
6.2.2 Transfer and Storage of Specimens
Ideally, aliquoted serum or plasma specimens should be stored immediately at –20oC.  If
specimens are to be transferred to a central facility they should be maintained at 4oC and shipped
on cold packs to the storage site.   If cold packs are not available, serum specimens can remain at
room temperature for up to 3 days, whereas whole blood hemolyzes over time.   Signed specimen
transfer sheets should accompany specimens during shipment. Upon receipt at the central facility,
specimens should be immediately transferred to a non-self-defrosting freezer for storage. Speci-
mens should be stored uniformly aliquoted and stored in a polypropylene tube. Specimen identi-
fiers should be labeled directly on the tube, and not on the screw-cap top.   Specimen inventories
should be maintained for storage freezers that are specifically reserved for reposited specimens.
Every effort should be made to limit the number of freeze-thaw cycles, since repetitive thaws may
result in loss of antibody titer and formation of serum flocculates. For long-term storage, speci-
mens should be frozen at –70oC.   
It is important to store these specimens with  all pertinent detailed information concern-
ing specimens  in a computer database or bound logbook, which is  periodically updated to reflect
specimen use or transfer.  Maintaining  this database and deposited specimens will facilitate addi-
tional evaluations at a later date.
6.2.3 To improve quality of sera for storage, the following steps 
may be followed:
• Centrifuge
• Pipette serum from clot rather than pouring the serum
• Filter the serum
• Make aliquots of serum to avoid multiple cycles of freezing and thawing
• Store at –70 degrees centigrade in non-self defrosting freezer
• Keep good daily freezer logs
• Exclude specimens that are:
Particulate
Lipemic
Hemolyzed
Contaminated with bacteria
Evaluation Materials — 25
Guidelines for Appropriate Evaluations of
HIV Testing Technologies in Africa
6.3 Serum Library:  Collection and use of stored serum
6.3.1 Characterization of Evaluation Panel
Characterization of the library of specimens used in the evaluation should be based on a
multi-test algorithm that allows for establishing a gold standard to determine serostatus.  Consid-
eration should be given for confirmation of only the positive samples by the Western blot for the
following reasons:
• Use of WB allows for characterization of sera to develop a panel for repeated use;   
• Use of the WB is recommended to allow countries to share evaluation data that repre-
sent standard confirmation methods and a more complete and accurate characteriza-
tion of specimens for evaluation. 
Although some countries may currently evaluate tests using only an EIA algorithm, coun-
tries should strive to adopt the WB for standardization and to increase data sharing.  
Is there a serum library of known positive and negative specimens?
Yes
No
Can specimen
integrity be verified?
(Section 4.3)
Collect sera and
characterize
Is QC and laboratory
infrastructure
adequate?
Yes
Select
evaluation
panel
Re-evaluate all
samples in library
OR
Collect new sera to
start library
Select proficiency
or reference panel
YesNo
Take
remedial
actions
Store for
use during
evaluations
No
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6.4 Trouble-shooting of problematic specimens
Occasionally, assays produce results that are difficult to interpret and are erroneous,
which may be due to factors inherent with the specimens or clerical errors. If such results occur,
consider the following:
• Check specimen integrity for evidence of bacteria contamination, hemolysis, and lip-
idic substances
• Verify labeling, paper-work, and procedures
• Re-check equipment and reagents
• Have the same technologist re-test the specimen 
• Repeat testing blindly by another technologist
• Repeat on reference test blindly 
• Repeat at different laboratory or reference laboratory
• Determine true status by other assays (PCR testing, p24) 
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7.0 Data Analysis
7.1 Data Management
Before collecting blood specimens, it is important to design a simple questionnaire and
tracking records for specimen management, which should include a unique specimen number,
date, and site of draw.  They may also include limited demographic information such as age, sex,
profession, and home district.  Tracking documents should include an inventory of specimens
being shipped, their origin, destination, and time and date of transfer.  Also  create  a database
that will allow the variables to be entered and linked with the associated specimen.  Such vari-
ables will include the unique specimen identification number, relevant tracking information, the
name of tests used, test results (positive or negative), optical density values, optical density ratios
(OD ratio), any additional confirmatory information such as WB pattern, and final determination
of sero-status (positive or negative).
7.2 Resolving Discordants 
There are two types of discordant results in an evaluation:  One such discordant is a spec-
imen that does not meet the criteria of positive or negative using the gold standard method/defi-
nition.   Before the evaluation, the laboratory should determine the gold standard for positives
and negatives.  In the case of an evaluation this may differ from normal testing practices, such as
the use of WB to confirm positive obtained in an evaluation setting.  An example of a discordant
result may be a specimen that is positive by EIA(s), but indeterminate on WB.   In the case of pro-
spective evaluation, the laboratory must ensure that  the reason for the discordant is not sample
mix-up or transcription error before deciding to perform additional testing to resolve these types
of discordants, such as p24 antigen testing or PCR.  Only the specimens that are positive or nega-
tive by the gold standard method should be used in calculating the sensitivity and specificity of
test performance.   The results of further testing may be listed in the evaluation summary to pro-
vide further information on the performance of tests used in the evaluation.
The second type of discordant result occurs  when the result of the test(s)  being evaluated
differs from the result of the gold standard.   An example might be a specimen that is negative
with the gold standard algorithm of EIA(s), but positive on one or more of the tests being evalu-
ated.   Once again the laboratory may decide to perform additional tests to provide further infor-
mation on the patient specimen; however, these results should not be included in calculating the
sensitivity and specificity.
7.3 Sensitivity, Specificity, PPV, NPV, Confidence Interval, 
Delta value, Reproducibility, Inter-reader variability  
Several key parameters need to be evaluated for each assay: sensitivity, specificity, posi-
tive and negative predictive values, and delta values. The sensitivity and specificity of each assay
are calculated using the gold standard.
Sensitivity is defined as the ability of an assay being evaluated to correctly detect speci-
mens containing antibody to HIV. In other words, sensitivity is the percentage of true positive
HIV specimens identified by the assay under evaluation as positive (A), divided by the number of
specimens identified by the reference assays as positive (A+C). 
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Specificity is defined as the ability of an assay being evaluated to correctly detect speci-
mens that do not contain antibody to HIV. In other words, specificity is the percentage of  true
negative specimens identified by the assay being evaluated as negative (D), divided by the num-
ber of specimens identified by the reference assays as negative (B+D).
Example: 
Evaluation of a rapid test on a panel of specimens that have been tested by the gold stan-
dard is shown to contain HIV antibodies to 300 serum samples and no HIV antibodies to 200
samples (Figure 3).   Of the 300 serum samples that were antibody positive, the rapid test classi-
fied 275 of the samples as positive.  Of the 200 samples that were HIV antibody negative by the
gold standard, 125 were classified by the rapid test as not containing HIV antibodies
Positive Predictive Value (PPV): is the probability that when the test is reactive, the spec-
imen actually contains antibody to HIV. PPV is calculated as follows: A/(A+B). PPV can also be
calculated as follows:
(prevalence) (sensitivity)
PPV =          
(prevalence) (sensitivity) + (1-prevalence)(1-specificity)
Negative Predictive Value (NPV):  is the probability that when a test is negative, a speci-
men does not have antibody to HIV. NPV is calculated as follows:  D/(C+D) or as:
(1-prevalence)(specificity)
NPV=
(1-prevalence)(specificity) +(prevalence)(1-sensitivity)
The proportion  of false positives and false negatives varies with the prevalence of HIV
infection in various segments of the population. In general, the higher the prevalence of HIV
infection in the population, the greater the probability that a person testing positive is truly
infected, i.e., the greater the positive predictive value (PPV). Thus, with increasing prevalence, the
Figure 3:  Results of Evaluation Panel Using Gold Standard
Gold Standard Results
+ –
Results of assay      +
Under evaluation     - 
A
True-positives 
275
B
False positives
75
A + B
350
C
False-negatives
25
D
True-negatives
125
C + D
150
  A + C  = 300 B+D = 200 500
Sensitivity=A/(A+C),  275/(275 + 25) = 91.67%
Specificity=D/(B+D), (125/(75 + 125) = 62.5%
Positive Predictive value=A/(A+B), 275/(275 + 75) = 78.57%
Negative Predictive value=D/(C+D), 125/(25 + 125) = 83.33%
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proportion of positive results that are false-positive decreases. Conversely, the likelihood that a
person having a negative test result is truly uninfected (i.e., the negative predictive value [NPV]),
decreases as prevalence increases. Therefore, as prevalence increases, so does the proportion of
samples testing false-negative. 
Confidence Interval (CI): The 95% confidence interval is an estimate of a population
parameter computed so that the statement “the population parameter lies in this interval” will be
true at a stated confidence, e.g., 95%.
95% CI of the calculated sensitivity and specificity are calculated using the formula:
P ± 1.96 
where P is the sensitivity or specificity
where N is the number of sera analyzed.
Delta value (∂)
Delta values are used to determine the ability of EIAs to separate the negative and posi-
tive anti-HIV serum populations from the cut-off. Delta (∂) values of the anti-HIV positive and
negative sample populations are calculated by dividing the mean Optical Density (OD) ratio
(log10) by the standard deviation of each population. OD ratios are calculated by dividing by the
relevant cut-off:
OD sample
OD ratio =  
OD cutoff
 In case of overflow, usually denoted as “****” in the print out, an OD of 3.000 is attributed
to the specimen. The higher the positive (∂+) and negative (∂ -) values, the higher the probability
that the test will clearly distinguish antibody positive and negative specimens. 
Reproducibility
To determine reproducibility, retest approximately 10% of the initially reactive and non-
reactive samples. Reproducibility, expressed as a percentage, is calculated by dividing the number
of concordant results by the total number of samples retested.
Inter-reader variability of rapid test
It is important to determine the inter-reader variability of rapid tests. Three persons inde-
pendently interpret each test result, and the reader variability is expressed as percentage of sera
for which different readers interpret test results differently.
P 1 P–( )
N--------------------
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8.0 Reporting Results, Conclusions, Recommendations
8.1 Developing an Algorithm
Evaluation data should be analyzed to determine the performance of individual tests and
the combination of tests used in a proposed algorithm.  In phase I, this will involve determining
the performance of various test combinations in addition to the individual test performance.  An
important point to consider in the analyzing potential algorithms is whether the tests will be per-
formed in a parallel or serial testing algorithm.  Most standard EIAs will be used in a serial algo-
rithm in which the use of the second test is dependent on a reactive result in the first test.   Many
rapid tests that are used in POS, however, may be tested in parallel logistical reasons.  A typical
example might involve determining the concordance of 2 tests performed in combination and
then evaluating the results when both tests agree (concordance) and when a 3rd test is required as
a tiebreaker because the first 2 tests have discordant results (Figure 4).
Samples in panel # 660 and #506 would have completely different interpretations in the
algorithm based on whether the tests were performed sequentially (Figure 4) or in  parallel.  This
is also true if the algorithm is a two test only or three tests with tiebreaker. The probable cause of
the difference in results in the EIA status vs. the rapid tests results is sample mix-up.
8.2 Reporting Results
Analysis of evaluation data should be completed and reported to the NAP, MOH, and
other partners immediately following the phase of evaluation in which it was performed, and
before beginning the next phase. 
The report for Phase I evaluation typically includes the data presented in a table that
itemizes the test methods, and the Se, Sp, PPV, NPV for each method and  combination of meth-
ods evaluated (Figure 5).   Phase II reports should include the on-site performance data in addi-
Figure 4:  Evaluation Methods
Panel EIA1 EIA2 Status Screening Conf Tiebreaker Algorithm
296 N N N N N N N
297* P P P N N N N
667 P P P P P P P
16 P P P P P P P
660 P P P P N N N
506 N N N N P P N
668 P P P P P N P
1,005 N N N N P N N
Raw dataset = 1,022 records
Final Panel = 972 specimens (360 positives / 612 negatives)
32  — Reporting Results, Conclusions, Recommendations
Guidelines for Appropriate Evaluations of 
HIV Testing Technologies in Africa
tion to the subjective input of the client/patient flow. Having completed Phase III of the
evaluation, countries should consider including the following recommendations in the final
report.
• The names and manufacturers of all EIA or rapid tests evaluated with documented test
performance
• The name and required specimen type for each test approved for use in POS settings
• The name of the test to be used as the tiebreaker for resolving discordant specimens
and justification for use
• The names and manufacturers of each test with demonstrable testing performance,
but excluded for use in POS setting.  Justifications for excluding tests should be
noted.  
• Summary of  individual test data
Figure 5.
Test Method Sensitivity Specificity PPV NPV
A 95% (190/200) 98% (294/300)
B 97% (194/200) 98.5% (295/300)
C 96% (192/200) 99% (297/300)
Algorithm Concordance
Sensitivity
(concordant 
results)
Specificity 
(concordant 
results)
PPV NPV
A and B 93% (475/500)
B and C 92% (460/500)
A and C
Example of evaluation of algorithm of tests performed in parallel
Test 
combination Tiebreaker Discordants
Combined sensitivity of 
concordant (2 tests) and 
discordant (3 tests)
Combined specificity of 
concordant (2 tests) and 
discordant (3 tests)
A and B 93% (475/500)
B and C 92% (460/500)
A and C
Test method combination with tiebreaker test for discordant results
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8.3 Aggregation and dissemination of evaluation data 
Conclusions and recommendations from evaluation of tests should be submitted to WHO
for access and dissemination to other countries within the region.   This compilation of test per-
formance will allow countries to review data from neighboring countries which should limit the
need for full-scale evaluations. 
The following should be included in the report to WHO:
• Protocol for evaluating tests, including designation of gold  standard
• Discordant results as tested by WB, if part of country’s gold standard
Summary reports should be submitted to:
Dr. Guy-Michel Gershy-Damet or Designate
Regional Advisor For Laboratory 
Regional Program on AIDS 
WHO Regional Office For Africa 
PO BOX BE 773 
Harare -Zimbabwe 
Tel: 263-4- 746342/827/323/359 
Fax: 263-4-746867 
Email: gershyg@whoafr.org
Phase I (n = # of samples) Phase II (n) Phase III (n)
Tests Se Sp Se Sp Se Sp
A
B
C
D
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Appendix A
Testing Algorithms
Parallel testing algorithm
In a parallel testing algorithm, sera are simultaneously tested by two assays.  True-posi-
tive sera are concordantly reactive by two different initial assays. A true-negative specimen in
the algorithm is defined as being concordantly negative in the two initial assays. Sera yielding
discordant results between the two assays are tested in a third assay, and the outcome of the latter
assay is considered definitive. 
Serial testing algorithm
The serial testing algorithm is most consistent with the proposed testing strategies of
WHO/UNAIDS [19].  In the serial algorithm, all specimens are tested by a first test that is highly
sensitive. Specimens are considered as true negative if they react negatively in the first test. Spec-
imens reactive in this assay are retested by a second assay that has a high specificity (this second
assay must be one which possesses dissimilar antigen presentations than that of the first assay.  If
specimens are concordantly positive by the two assays, they are considered as true-positives. Dis-
cordantly reactive sera are further tested by a third assay, whose outcome is considered as defini-
tive.  This algorithm is recommended for identification of asymptomatic seropositive persons in
areas with an HIV seroprevalence of more than 10% [20]. 
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Appendix B
Summary of WHO Testing Strategies 
WHO Strategy I:
• Requires one test. 
• For use in diagnostic testing in populations with an HIV prevalence >30% among
persons with clinical signs or symptoms of HIV infection.
• For use in blood screening, for all prevalence rates.
• For use in surveillance testing in populations with an HIV prevalence >10% (e.g.,
unlinked anonymous testing for surveillance among pregnant women at antenatal
clinics). No results are provided. 
WHO Strategy II:
• Requires up to two tests.
• For use in diagnostic testing in populations with an HIV prevalence <30% among
persons with clinical signs or symptoms of HIV infection or >10% among asymptom-
atic persons.
• For use in surveillance testing in populations with an HIV prevalence <10% (e.g.,
unlinked anonymous testing for surveillance among patients at antenatal clinics or
sexually transmitted infection clinics). No results are provided.
WHO Strategy III:
• Requires up to three tests.
• For use in diagnostic testing in populations with an HIV prevalence = 10% among
asymptomatic persons.
• Alternative approaches that address limitations to these strategies are addressed in
WHO/UNAIDS and surveillance documents.
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Appendix C
Potential Testing Strategies
Note:
1. This is a very limited review based on experiences of CDC investigators and collaborators.
2. Choice of screening/confirmation order should be based on review of sensitivity and
specificity in country.  Examples above are starting points based on work in several countries.
(Tests like Determine and Capillus have high sensitivity and are designed as screening tests but
consistently give some false positives, therefore, are not recommended as confirmatory tests). 
Screening Confirmation
Whole Blood Determine HIV 1/2 HemaStrip HIV 1/2
UniGold HIV Recombinant
OraQuick HIV –1/2
HemaStrip HIV 1/2 UniGold HIV Recombinant
OraQuick HIV – 1/2
OraQuick HIV1/2 HemaStrip HIV1/2
UniGold HIV Recombinant
Serum / Plasma Capillus HIV 1/2 SeroCard HIV
MultiSpot HIV 1/2
HIVChek System 3
SeroStrip HIV 1/2
HIVSav 1&2
DoubleCheck HIV 1&2
Genie II HIV1/2
HIVSpot HIV
HIVSpot HIV SeroCard HIV
SeroStrip HIV 1/2
DoubleCheck HIV 1/2
Genie II HIV 1/2
HIVSav 1&2
Determine HIV 1/2 SeroCard HIV
SeroStrip HIV 1/2
DoubleCheck HIV 1/2
Genie II HIV 1/2
HIVSpot HIV
MultiSpot HIV 1/2
Oral Fluids OraQuick HIV 1/2 Saliva-Strip HIV1/2
SalivaCard HIV
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Appendix E
Laboratory Safety Rules
 Important rules, not necessarily in order of importance, should be adhered to when work-
ing in a laboratory:
 1. Pipetting by mouth should be prohibited.
 2. Eating, drinking, smoking, storing food and applying cosmetics must not be permitted
in the laboratory/testing work areas.
 3. Labels must not be licked, materials must not be placed in the mouth
 4. The laboratory/testing site should be kept neat, clean, and free of materials that are
not pertinent to the work.
 5. Work surfaces must be decontaminated imediately after any spill of potentially dan-
gerous material and at the end of the working day.
 6. Members of the staff must wash their hands after handling infectious materials, and
before they leave the laboratory.
 7. All technical procedures should be performed in a way that minimizes the formation
of aerosols and droplets.
 8. All contaminated materials and specimens must be decontaminated before disposal or
cleaning for reuse.  They should be placed in a leak-proof, color- coded plastic bag for
autoclaving or incineration on the premises.  These bags should be supported in rigid
containers.  If it is necessary to move the bags to another site for decontamination,
they should be placed in leak-proof containers e.g., solid-bottomed, that can be closed
before they are removed from the laboratory.
 9. Laboratory coveralls, gowns or uniforms must be worn for work in the laboratory.
This clothing should not be worn in non-laboratory areas such as offices, libraries,
staff rooms and canteens.  Contaminated clothing must be decontaminated by appro-
priate methods.
10. Open-toed footwear should not be worn.
11. Protective laboratory clothing should not be stored in the same lockers or cupboards
as street clothing.
12. Safety glasses face shields (visors) or other protective devices must be worn when it is
necessary to protect the eyes and face from splashes and impacting objects. 
13. Only persons who have been advised of the potential hazards and who meet specific
entry requirements (e.g. immunization) should be allowed to enter the laboratory
working areas.  Laboratory doors should be kept closed when work is in progress;
children should be excluded from laboratory working areas.
14. There should be an insect and rodent control program.
15. Gloves appropriate for the work must be worn for all procedures that may involve
accidental direct contact with blood, and infectious materials.  After use, gloves
should be removed aseptically and autoclaved with other laboratory wastes before
disposal.  Hands must then be washed.  Do not wash or disinfect surgical or examina-
tion gloves for reuse. 
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16. All spills, accidents and overt or potential exposures to infectious materials must be
reported immediately to the laboratory supervisor.  A written record of such accidents
and incidents should be maintained.
17. Appropriate medical evaluation, surveillance and treatment should be provided.
18. Baseline serum samples may be collected from laboratory staff and other persons at
risk.  These should be stored as appropriate.  
19. The laboratory supervisor should ensure that training in laboratory safety is provided.
A safety or operations manual that identify known and potential hazards and that
specifies practices and procedures to minimize or eliminate such hazards should be
adopted.  Personnel should be advised of special hazards and required to read and fol-
low standard practices and procedures.  The supervisor should make sure that person-
nel understand these.
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Appendix F
Sample Evaluation Expenditures
Test Kits Cost
Kit –1
Kit –2
Kit –3
HIV Western Blot
Reagents
$4,000
$3,000
$6,000
$2,500
$2,000
Supplies
Fine tips
Vaccutainer tubes with needles
General (expendable) supplies
$2,500
$2,250
$2,000
Monitoring and Evaluation 
Laboratory personnel 
Onsite Checks
Proficiency testing
Travel expenses
$1,000
$248
$2000
HIV Western Blot $2500
HIV Reagents $2,000
Total Budget for 6 Months $27,498 US
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Appendix G
Sample Contents of an Evaluation Protocol 
Introduction
Purpose
Literature review
Limitations
Methods
Specimens required
Study sites
Study populations
Sampling
Sample size
Budget
Kits (ELISA, rapids, +/- WB, P24 Ag, PCR)
Bench expenses (non-kit reagents, pipette tips, time, technicians, equipment costs.
Transport of specimens and personnel
Use of panels and libraries
Venipuncture and collection equipment
Storage cryotubes
Training of lab and field staff
IQA, IQC, EQA
Data management and storage
Implementation
Time frames
Staff duties
Analysis
Reporting and Publishing results
Results
Statistical calculations
Ethical issues
References
Appendices
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